Would you offer definitive local therapy to a patient with ER/PR+, Her2 neg breast cancer with oligometastatic disease that responded well to CDK 4/6 inhibitor +AI, despite NRG-BR002 results?

The description of "ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligo-metastatic disease in the right 4th rib (near primary tumor but not clearly direct extension) and good response to 6 months of AI+CDK4i" suggests that the primary breast cancer is intact. The...

Agree with @Dr. First Last, we approach in the same manner in ER+/HER2- breast patients with favorable response on systemic therapy -- don't offer SBRT with good response on systemic therapy.

In the setting of true oligoprogression in ER+/HER2- tumors at primary site or at known met while on AI/CDK...